RESEARCH ON THE EFFECTIVENESS OF MULTIFUNCTIONAL PEP-
TIDE PREPARATION REVILAB ML 09 IN OSTEOCHONDROSIS OF
THE LUMBOSACRAL SPINE
Study period — April 2016 – November 2018
Location — Russia, Moscow, Moscow office of the Peptides
Research and Production Center of Revitalization and Health
Actual enrolment — 83 participants
Age — 43–56 y.o.
Dosage regimen — 1 capsule in the morning a. c. daily
Period of administration — 4 months
The research included patients with general degenerative changes, as well as with Schmorl’s
nodule and moderate intervertebral disc protrusions.
RESEARCH RESULTS OF THE EFFECTIVENESS OF THE PEPTIDE
BIOREGULATOR REVILAB ML 09 IN OSTEOCHONDROSIS OF THE
LUMBOSACRAL SPINE
Parameter Placebo Placebo ML 09 ML 09 group
group before group after group before after treatment,
treatment, treatment, treatment,
43 participants 43 participants 40 participants 40 participants
Pain and 39 (91%) 36 (84%) 36 (90%) 12* (30%)
discomfort
Limitation of 24 (56%) 19 (44%) 22 (55%) 9* (23%)
motion
Improvement ― None ― 32* (80%)
in infrared
thermography
Improvement ― None ― 27* (68%)
in X-ray and
computed
tomography
*Accurate changes in comparison with the placebo group.
113 // Health territory. PEPTIDES. A Few Words on Joints
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.